甲磺酸阿帕替尼对晚期宫颈癌患者预后的影响研究

目的 探究甲磺酸阿帕替尼对标准方案治疗失败的晚期宫颈癌患者预后的影响.方法 将120例晚期宫颈癌患者按治疗方案的不同分为对照组45和观察组75例,对照组采取二线或二线以上化疗方案,观察组采取甲磺酸阿帕替尼联合二线或二线以上化疗方案.比较两组患者近期疗效客观有效率(ORR)、疾病控制率(DCR)]、不良反应、远期预后...

Effect of apatinib mesylate on the prognosis of patients with advanced cervical cancer

Objective To investigate the effect of apatinib mesylate on the prognosis of patients with advanced cervical cancer who have failed the standard regimen.Method A total of 120 patients with advanced cervical cancer were divided into a control group of 45 patients and an observation group of 75 patients according to different treatment regimens.The control group received second-line or more rounds of chemotherapy treatment,and the observation group received the regimen based on apatinib mesylate combined with the control group s option.The short-term efficacyobjective response rate(ORR),disease control rate(DCR)],adverse events,long-term prognosissurvival rate,median survival(OS)and median progression-free survival(PFS)]and prognostic factors were compared between the two groups of patients.Result The ORR and DCR of the observation group were 61.33%(46/75)and 86.67%(65/75),respectively,which were higher than 42.22%(19/45)and 71.11%(32/45)of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse events between the two groups of patients(P>0.05).The median OS of the observation group was 20.00 months,which was longer than 14.68 months m the control group,and the difference was statistically significant(P<0.05).The median PFS of the observation group was 15.20 months,which was longer than the control group s 10.98 months,the difference was statistically significant(P<0.05).Univariate analysis indicated that there was a statistically significant difference m the 3-year survival rate of patients with advanced cervical cancer in the number of metastases,clinical stages,and treatment options(P<0.05).The further multifactor analysis showed that the number of tumor metastasis site>1,clinical stageⅣ,and chemotherapy alone are independent risk factors for predicting OS in patients with advanced cervical cancer.Conclusion When standard treatment fails,apatmib mesylate combined with second-line or third-line chemotherapy can improve the short-term efficacy and longterm prognosis of patients with advanced cervical cancer with the mild adverse event and acceptable safety.